



August 27, 2014

## Surgeon Performs Live Sleeve Gastrectomy Telesurgery at International Conference Using TransEnterix's New Flex Ligating Shears

MONTREAL--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the broadcast of a successful sleeve gastrectomy surgery by Dr. Helmuth Billy at the 5<sup>th</sup> International Conference on Sleeve Gastrectomy to help kick off the 2014 19th World Congress of the International Federation for the Surgery of Obesity & Metabolic Disorders (IFSO) meeting in Montreal, Canada. Dr. Billy performed the innovative surgery from across the globe at Hamad General Hospital in Doha, Qatar using TransEnterix's Flex Ligating Shears, the only fully flexible advanced energy device available that offers ligation and division with direct thermal fusion.

Seen globally by more than 400 surgeons, this was the first broadcast of a case utilizing the Flex Ligating Shears advanced energy device at a major bariatric surgical conference. The Flex Ligating Shears received 510(k) clearance from the U.S. Food and Drug Administration and is the only advanced energy device that completely articulates 360 degrees to provide optimal angles and access to surgeons within the operating field.

"The Transenterix Flex Ligating Shears allows for significantly more complex tasks to be performed utilizing the flexible articulating channels of their platform," said Dr. Helmuth Billy, Director of Bariatric Surgery at St. John's Regional Medical Center in Oxnard, CA. "The device gives me a fully flexible and controllable tissue sealing option that works well at limiting bleeding and creates little to no smoke that would impair my vision."

"We are pleased Dr. Billy was chosen to perform a live gastric sleeve procedure using the new TransEnterix Flex Ligating Shears at such a prestigious global surgical conference," said Todd M. Pope, President and CEO of TransEnterix. "Advanced energy is utilized in some of the most critical tasks amongst the millions of minimally invasive surgeries performed worldwide. Our flexible device, which utilizes thermal fusion technology, allows surgeons to precisely deliver energy at the desired angles. We believe this device is preparing TransEnterix to be a meaningful player in the multi-billion dollar advanced energy market, especially when combined with the advantages of robotic assistance with our SurgiBot system expected to be launched in 2015."

Advanced energy devices represent one of the most versatile and crucial tools for surgeons in minimally invasive surgery. These devices deliver controlled energy to effectively ligate and divide tissue while greatly limiting bleeding in the operative field and minimizing thermal injury to surrounding structures.

TransEnterix's advanced energy device has been created for use with the company's existing surgical system to support the expansion of single incision surgery for reduced incisions and scarring. The company intends to offer a similar device in the future for its SurgiBot™ system, a new patient-side robotic surgery system currently under development.

### About TransEnterix

TransEnterix is a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery. The company is focused on the development and commercialization of the SurgiBot system, a minimally invasive surgical robotic system that allows the surgeon to be patient-side within the sterile field. For more information, visit the company's website at [www.transenterix.com](http://www.transenterix.com)

### Forward Looking Statements

*This press release includes statements relating to our advanced energy device and SurgiBot system, as well as our current regulatory and commercialization plans for the system. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations, including whether TransEnterix will become a meaningful player in the advanced energy market, especially when combined with the advantages of robotic assistance with our SurgiBot system expected to be launched in 2015. Factors that could cause our results to differ materially from those described include but are not limited to: the pace of adoption of our product technology by surgeons, including the Flex Ligating Shears Advanced Energy Device; whether the Flex Ligating Shears can offer surgeons the ability to attain precise angles when cutting and dividing tissue in a laparoscopic procedure; the success and market opportunity of our*

*continuing and new product development efforts, including the SurgiBot system; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2013 filed on March 5, 2014, as amended; and subsequent SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.*

**Media Contact:**

Grey Matter Marketing

Joanna Rice, 951-751-1858

[Joanna@greymattermarketing.com](mailto:Joanna@greymattermarketing.com)

or

**Investor Contact:**

Westwicke Partners

Mark Klausner, 443-213-0501

[transenterix@westwicke.com](mailto:transenterix@westwicke.com)

Source: TransEnterix, Inc.

News Provided by Acquire Media